Phase 3 N=185 Safety Study of Oral Edaravone Administered in Subjects With ALS
ALS
Primary: Number of Treatment Emergency Adverse Events — 961 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Palbociclib With Everolimus + Exemestane In BC
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Hormone Receptor (HR)-Positive Breast Cancer
Primary: Clinical Benefit Rate (CBR) [Phase 2a] — 6 Participants
Phase 3 N=266 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx · Oral Mucositis
Primary: Duration of Severe Oral Mucositis (SOM) — 12.5; 20.0 days — p=0.1798
Phase 2 N=94 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
Acute Myelogenous Leukemia · AML
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities — 0; 1 Participants
Phase 3 N=342 A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis
Osteoarthritis of the Knee
Primary: Change in Knee Pain — -0.96; -1.10 score on a scale — p=0.26
N/A N=33 Mind Your Heart Study
Medication Non-adherence
Primary: Retention Rate — 31; 29 Participants
Phase 4 N=10 Abatacept in Juvenile Dermatomyositis
Dermatomyositis
Primary: Number of Patients Meeting the Definition of Improvement (DOI) at Week 24: at Least 3 of 6 Core Set Measures (CSM) Improved by ≥ 20% With no More Than 2 CSM Worsening by…
Phase 3 N=257 Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
Epilepsy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study — 94.4; 93.3; 93.6; 92.3 percentage of participants
N/A N=58 Correction of Farsightedness in Children Study
Hyperopia · Farsightedness
Primary: Change in Kaufman Test of Educational Achievement (K-TEA) Reading Comprehension Score as Measured From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or…
Early Phase 1 N=8 NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
Gliosarcoma · Recurrent Glioblastoma
Primary: Number of Patients With Adverse Events — 8; 4; 1; 0 Participants
Phase 4 N=92 Ideal Steroids for Asthma Treatment in the PICU
Asthma Childhood
Primary: Length of Stay — 2.9; 2.9 days — p=0.632
Phase 4 N=12 Growth and Development Study of Alglucosidase Alfa
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
Primary: Recumbent Height/Length of Participants in Centimeters (cm) — 80.4; 93.8; 67.7; 91.1 cm
Phase 2 N=104 Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
Atopic Dermatitis · Plaque Psoriasis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6 for AD Participants — -35.5; -74.9 Percent Change — p=0.0004
Phase 2 N=19 Dextromethorphan in Fibromyalgia
Fibromyalgia
Primary: Daily Self-reported Pain Severity — 41.09; 45.55 score/day — p=0.146
Phase 4 N=61 Phosphate Lowering in CKD Trial
Chronic Kidney Disease · Cardiovascular Disease
Primary: Brachial Artery Flow-mediated Dilation — 3.13; 3.74; 2.73; 3.09 percent change FMD